See more : Brookfield Infrastructure Partners L.P. (BIP-PB) Income Statement Analysis – Financial Results
Complete financial analysis of Q BioMed Inc. (QBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Q BioMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zhejiang Tiantai Xianghe Industrial Co.,Ltd. (603500.SS) Income Statement Analysis – Financial Results
- Cadeler A/S (CDLR) Income Statement Analysis – Financial Results
- BLICK GLOBAL GROUP AB (BLICK.ST) Income Statement Analysis – Financial Results
- Boundary Gold and Copper Mining Ltd. (PRZFF) Income Statement Analysis – Financial Results
- NJS Co., Ltd. (2325.T) Income Statement Analysis – Financial Results
Q BioMed Inc. (QBIO)
About Q BioMed Inc.
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.35K | 195.60K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 293.34K | 246.85K | 326.01K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 | 38.05K | 0.00 |
| Gross Profit | -8.99K | -51.25K | -296.01K | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 | -38.05K | 0.00 |
| Gross Profit Ratio | -3.16% | -26.20% | -986.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 125.38K | 1.07M | 1.88M | 3.54M | 3.24M | 3.10M | 1.31M | 598.00K | 0.00 | 0.00 |
| General & Administrative | 3.28M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Selling & Marketing | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.31M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Other Expenses | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.44M | 7.34M | 12.85M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Cost & Expenses | 3.73M | 7.58M | 13.18M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Interest Income | 0.00 | 506.92K | 296.22K | 1.46M | 0.00 | 138.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38M | 506.92K | 296.22K | 1.46M | 162.10K | 760.31K | 480.29K | 14.51K | 0.00 | 0.00 |
| Depreciation & Amortization | 50.00K | 50.00K | 50.00K | 50.00K | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 0.00 |
| EBITDA | -617.63K | -7.68M | -13.15M | -7.97M | -89.00K | -1.41M | -344.72K | -119.97K | 0.00 | -500.00 |
| EBITDA Ratio | -217.21% | -3,751.88% | -43,651.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.45M | -7.39M | -13.15M | -8.02M | -9.02M | -12.37M | -6.35M | -952.14K | -38.05K | -500.00 |
| Operating Income Ratio | -1,211.74% | -3,777.44% | -43,818.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.39M | -851.99K | -346.78K | -2.26M | -251.10K | -2.17M | -825.00K | -134.48K | 0.00 | 0.00 |
| Income Before Tax | -2.05M | -8.24M | -13.49M | -10.28M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Income Before Tax Ratio | -721.67% | -4,213.02% | -44,973.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 506.92K | 296.22K | 1.46M | 251.10K | 760.18K | -5.87M | -937.63K | 0.00 | 0.00 |
| Net Income | -2.05M | -8.75M | -13.79M | -11.74M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Net Income Ratio | -721.67% | -4,472.19% | -45,961.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| EPS Diluted | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
| Weighted Avg Shares Out (Dil) | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
Q BioMed bolsters commercialization of Strontium89 with EVERSANA partnership
Q BioMed Inc announced it has engaged EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, to immediately support the commercialization of Strontium89. Strontium89 (Strontium Chloride Sr-89 Injection, USP) is the only US Food and Drug Administration-approved...
Q BioMed raises $2M with plans for uplisting on NASDAQ; updates on activity for coming months
Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 months. The uplisting on a senior...
Q BioMed raises $2M with plans for uplisting on NASDAQ, shares plans for upcoming months
Q BioMed Inc announced that the company closed an additional $2 million funding on October 5 this year, which will be used to support its planned uplisting to Nasdaq and operations for the next 12 months. The uplisting on a senior...
Q BioMed sees uptick in 4Q sales of Strontium89 amid commercial rollout
Q BioMed Inc. has seen an uptick in Strontium89 (Strontium Chloride Sr-89 Injection, USP) sales in its fourth quarter. As a result, the company said it is projecting its 4Q revenue will likely double that in previous quarters.
Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in Strontium89 (Strontium Chloride Sr-89 Injection, USP)...
Q BioMed says its MAN-19 therapeutic for Acute Respiratory Distress Syndrome (ARDS) poised to start clinical trials next year
Q BioMed Inc said its MAN-19 therapeutic, which it is developing with partner Mannin Research, is poised to start clinical trials in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is being assessed to treat acute respiratory distress...
Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a condition caused by...
Q BioMed expects South Korean patent for its liver cancer chemotherapy candidate
Q BioMed Inc said it has received a Notice of Allowance for the patent of its Uttroside B asset in South Korea, adding to the patents already secured in Canada and Japan for the liver cancer chemotherapy candidate. The company...
Q BioMed strikes distribution agreement for Strontium89 sales in Canada
Q BioMed Inc. has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries. Under the terms...
Q BioMed inks license deal with Clionix for sales of Strontium89 in Europe and the Middle East
Q BioMed Inc (OTCQB:QBIO) revealed that it has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the company's metastatic bone pain drug Strontium89. The New York-based biotech said that...
Source: https://incomestatements.info
Category: Stock Reports